Applied Biosystems and Asuragen collaborate with the Critical Path Institute to improve drug toxicity screening

10-Nov-2008 - USA

drug toxicity is a leading cause of pre-clinical drug failures. The US food and Drug Administration (FDA) and other regulatory organisations have called upon the pharmaceutical industry to develop more effective tools to help avoid these costly failures, reduce the number of failed compounds, and bring better drugs to market sooner. To help address this challenge, Applied Biosystems Inc. and Asuragen, Inc. are collaborating with the Critical Path Institute’s Predictive Safety Testing Consortium to develop a predictive gene signature panel that will allow pharmaceutical companies to screen potential therapeutics quickly and easily for toxic effects in pre-clinical samples.

As part of the collaboration, Critical Path Institute (C-Path), Applied Biosystems and Asuragen will partner to develop a panel of assays with gene targets determined to be associated with carcinogenicity in laboratory rats, a common model organism for pharmaceutical testing. The collaborators will also use the Applied Biosystems assays to determine and differentiate effects that are genotoxic from non-genotoxic modes of action to assist in risk assessment. The new biomarker panel will be based on Applied Biosystems’ TaqMan® Gene Signature Array and real-time PCR technology.

“The development of robust turnkey assays to speed development of therapeutics for patients is one of the fundamental goals of the Critical Path Initiative, for which we believe we can make a difference working with partners such as Applied Biosystems and Asuragen,” said Dr William B Mattes, director of C-Path’s Predictive Safety Testing Consortium. “We expect this collaboration will facilitate broader utility of genomic biomarkers of toxicity across the industry in order to enable the early prediction and mechanistic understanding of potential carcinogens in pre-clinical research.”

The Predictive Safety Testing Consortium (PSTC) was established by C-Path to bring together major pharmaceutical companies to work in collaboration with C-Path and in coordination with the FDA. Its objective is to enable the exchange of knowledge and resources to speed drug development and improve drug safety. The Consortium currently has 16 members. Scientists from the FDA and its European counterpart, the European Medicines Agency, as well as academic experts also participate as advisors.

https://www.bionity.com/en/news/89349/applied-biosystems-and-asuragen-collaborate-with-the-critical-path-institute-to-improve-drug-toxicity-screening.html